ConductScience.org, home

Paper42569746

The Regeneration Paradox in Liver Cancer: How Chronic Injury Transforms Healing into Carcinogenesis.

Yeh CN and 1 other. Liver Cancer, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. The Regeneration Paradox in Liver Cancer: How Chronic Injury Transforms Healing into Carcinogenesis. Papers, record 42569746. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42569746

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The Regeneration Paradox in Liver Cancer: How Chronic Injury Transforms Healing into Carcinogenesis.
PubMed
Journal
Liver Cancer
PubMed
Year
2026
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-08-13
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Yeh CNChun-Nan
2Chen MFMiin-Fu

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References75

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
120078217The senescence-associated secretory phenotype: the dark side of tumor suppression.Annu Rev Pathol2010https://conductscience.org/library/papers/20078217PubMed
230136421Integrating the Epigenome to Identify Drivers of Hepatocellular Carcinoma.Hepatology2019https://conductscience.org/library/papers/30136421PubMed
335798016Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial.Lancet Oncol2022https://conductscience.org/library/papers/35798016PubMed
426099527Genetic Landscape and Biomarkers of Hepatocellular Carcinoma.Gastroenterology2015https://conductscience.org/library/papers/26099527PubMed
511844509Laparoscopic living donor hepatectomy for liver transplantation in children.Lancet2002https://conductscience.org/library/papers/11844509PubMed
625132496ER stress cooperates with hypernutrition to trigger TNF-dependent spontaneous HCC development.Cancer Cell2014https://conductscience.org/library/papers/25132496PubMed
722516259Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4.Cancer Cell2012https://conductscience.org/library/papers/22516259PubMed
818563841Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression.Hepatology2008https://conductscience.org/library/papers/18563841PubMed
933090190The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma: A Review.JAMA Oncol2021https://conductscience.org/library/papers/33090190PubMed
1019308066Linking DNA methylation and histone modification: patterns and paradigms.Nat Rev Genet2009https://conductscience.org/library/papers/19308066PubMed
1125747274β-Catenin Signaling and Roles in Liver Homeostasis, Injury, and Tumorigenesis.Gastroenterology2015https://conductscience.org/library/papers/25747274PubMed
1220951342The hippo signaling pathway in development and cancer.Dev Cell2010https://conductscience.org/library/papers/20951342PubMed
1312395331Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus.Hepatology2002https://conductscience.org/library/papers/12395331PubMed
1438572751Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2024https://conductscience.org/library/papers/38572751PubMed
1530765123Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study.Lancet2019https://conductscience.org/library/papers/30765123PubMed
1618552846Combinatorial patterns of histone acetylations and methylations in the human genome.Nat Genet2008https://conductscience.org/library/papers/18552846PubMed
1735325622Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial.Lancet Gastroenterol Hepatol2022https://conductscience.org/library/papers/35325622PubMed
1825294808Epigenetic signatures of alcohol abuse and hepatitis infection during human hepatocarcinogenesis.Oncotarget2014https://conductscience.org/library/papers/25294808PubMed
1935484418Molecular pathogenesis and systemic therapies for hepatocellular carcinoma.Nat Cancer2022https://conductscience.org/library/papers/35484418PubMed
2030287171Targeted and Immune-Based Therapies for Hepatocellular Carcinoma.Gastroenterology2019https://conductscience.org/library/papers/30287171PubMed

See all 75 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42569746

GET https://conductscience.org/api/papers/v1/42569746/references?page=2